^
Association details:
| Biomarker: | HER-2 M774delinsWLV |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Vizimpro (dacomitinib) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib
Published date:
09/13/2023
Excerpt:
Both EGFR exon 20 insertional mutation (Ex20ins) and HER2 Ex20ins demonstrated significant internal heterogeneity in response to dacomitinib, among which specific subtypes (including EGFR D770delinsGY, A763_Y764insFQEA, and HER2 M774delinsWLV) were highly sensitive. Other uncommon EGFR mutations including 18del and L747P have also been shown responsive to dacomitinib.
DOI:
10.21037/tcr-23-95
Source:
Title:
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
Excerpt:
Description of HER2 mutations and clinical outcomes of patients treated with dacomitinib….The activity of dacomitinib in patients with HER2 mutations in this trial confirms the earlier reports of benefit with HER2 kinase inhibitors in similar patients.
DOI:
10.1093/annonc/mdv186
Trial ID:
